+44 (0) 1753 578 080

[email protected]

Author: jacob

  • Expanding Clinical Trials for Rare Cancers: A Must for NHS 2035 Targets.

    Expanding Clinical Trials for Rare Cancers: A Must for NHS 2035 Targets.

    The National cancer plan 2026 sets out one of the most ambitious shifts in UK oncology policy in a generation. Its headline aim is clear: by 2035, three in four people diagnosed with cancer in England should be cancer-free or living well five years after diagnosis, compared with around 60% today. Achieving that target will…

  • Amyotrophic Lateral Sclerosis (ALS) Guide

    Amyotrophic Lateral Sclerosis (ALS) Guide

    Amyotrophic lateral sclerosis (ALS) is a progressive neurological condition that affects motor neurons in the brain and spinal cord. These nerve cells control voluntary muscle movement. As ALS progresses, motor neurons deteriorate and die, leading to increasing muscle weakness and loss of physical function. What Is ALS? Motor neurons transmit signals from the brain and…

  • What is World Cancer Day and Why Does Clinical Oncology Research Make a Difference?

    What is World Cancer Day and Why Does Clinical Oncology Research Make a Difference?

    World Cancer Day, observed each year on 4th February, is a global initiative focused on raising awareness of cancer and accelerating action across prevention, diagnosis, treatment and research. For organisations working in clinical research and drug development, the day is also an opportunity to reflect on the progress made, and the work still required to…

  • Understanding Chordoma and the Role of Clinical Research

    Understanding Chordoma and the Role of Clinical Research

    Chordoma is a very rare cancer, diagnosed in only around one in a million people each year. It develops slowly, close to critical structures in the spine and skull base, meaning treatment can be complex and the path to diagnosis long. With limited therapeutic options and a high risk of recurrence, continued oncology-led clinical research…

  • New Clinical Research strengthens evidence for CAR T-cell treatment for blood cancer

    New Clinical Research strengthens evidence for CAR T-cell treatment for blood cancer

     A new study by scientists at University College London and Great Ormond Street Hospital has demonstrated promising results in the treatment of T-cell acute Lymphoblastic Leukaemia (T-ALL), a rare and aggressive blood cancer What the study reveals. This groundbreaking research introduces BE-CAR7, a world-first base-edited Chimeric antigen receptor (CAR) T-cell therapy used in humans. The…

  • Alpha-1 Antitrypsin Deficiency: The Importance of Earlier Diagnosis and Clinical Research

    Alpha-1 Antitrypsin Deficiency: The Importance of Earlier Diagnosis and Clinical Research

    Alpha-1 Antitrypsin Deficiency (AATD) is a hereditary condition that increases the risk of serious lung and liver disease. It occurs when the body produces too little of a protective protein called Alpha-1 Antitrypsin (AAT). Without adequate AAT, lung tissue becomes more susceptible to inflammation and progressive damage, while abnormal protein can build up in the…

  • Duchenne Muscular Dystrophy: Causes, Symptoms, Inheritance and Clinical Research

    Duchenne Muscular Dystrophy: Causes, Symptoms, Inheritance and Clinical Research

    Duchenne muscular dystrophy (DMD) is a rare genetic disorder that causes progressive muscle weakness and wasting. It primarily affects males and is one of the most common and severe forms of muscular dystrophy. Understanding the causes, inheritance, and symptoms of Duchenne muscular dystrophy is essential for improving diagnosis, care, and advancing research into new therapies.…

  • How does AI-enabled causal modelling support discussions with potential investors?

    How does AI-enabled causal modelling support discussions with potential investors?

    Welcome back to our blog series where we share some of the highlights and key takeaways from our fireside chat with CEO of Simbec-Orion, Fabrice Chartier, and CEO of biotx.ai, Joern Klinger. Our last blog post covered what AI-enabled causal modelling is, how it is different from other models, and where you might want to…

  • Can early utilisation of AI-enabled causal modelling de-risk and accelerate clinical development?

    Can early utilisation of AI-enabled causal modelling de-risk and accelerate clinical development?

    Can early utilisation of AI de-risk and accelerate clinical development for drug developers? Recent announcements suggest large pharma companies are betting big on AI. AstraZeneca recently announced a $247 million deal with an AI vendor to support identifying new oncology drug candidates[1]. Sanofi has announced a collaboration with two separate AI vendors, worth up to…

  • The Impact of Clinical Trials on MS Research and Care

    The Impact of Clinical Trials on MS Research and Care

    Clinical trials are essential in advancing treatments for multiple sclerosis (MS). With no cure currently available, ongoing research is critical to uncovering new, more effective therapies. Simbec-Orion is a Clinical Research Organisation with nearly five decades of experience, specialising in oncology and rare diseases. This article explores the vital role that clinical trials play in…